Tissue types and indications
Access advanced preclinical disease models utilizing viable, intact human tissue. Evaluate your therapies across our liver, lung, and kidney precision cut tissue slice platforms to reveal exactly how compounds behave in real human disease.
Eventually, every drug meets human biology
Our platform utilizes viable, intact human liver, lung and kidney tissue sourced through our established clinical network. By working directly in living human tissues, you can move beyond surrogate assumptions and generate evidence with the human relevance needed to support confident decisions.
Built on deep expertise in fibrosis, inflammation and related disease biology, our platform enables direct assessment of therapeutic response in human pathology. This helps you explore mechanism of action, validate targets and assess therapeutic response earlier in development, replacing biological guesswork with decision-grade evidence you can use with confidence.
Liver
Test therapies in viable, intact human liver tissue across models of inflammation, fibrosis and steatosis, with direct comparison to approved standard-of-care therapies.
Lung
Test how your interventions can block the induction of disease in healthy PCTS or therapeutically attenuate existing disease in PCTS prepared from clinically diagnosed explant lung tissue (IPF, ILD, PPF, COPD).
Kidney
Investigating your asset in acute kidney injury and chronic kidney disease models in our PCTS platforms.
Built for broader biological insight
Our platform supports a range of biological studies beyond fibrosis and inflammation. This gives you scope to explore different mechanisms, disease processes and research questions in a human-relevant system.
The same platform is also applied across multiple therapeutic modalities, including small molecules, antibodies, peptides, proteins, AAVs, ADCs, ADCCs, ASOs and LNPs, each assessed in the same preserved human tissue environment.
Reliably sourced. Incomparably real.
We source viable, intact human tissue through established clinical partnerships that ensure ethical procurement and reliable access to both healthy and diseased organs, allowing studies to be shaped around defined clinical profiles where needed.
How can we support your next program?
Speak with our team about how specific tissue types and disease models can be applied to your research.
Enabled by our tissue bioreactor technology
To accurately predict how a treatment will perform, you need a model that maintains tissue architecture, cellular complexity and preserves the extracellular matrix. Our bioreactor technology maintains intact human tissue from a range of organs for an extended duration, allowing you to observe how your therapy behaves in real human biology.
Related resources
Explore our insights to learn more about how data generated in viable, intact human tissue supports lead prioritization and reduces uncertainty in early development.
Poster
Combination of an Acetyl-Coenzyme A Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in Human Precision-Cut Liver Slices
See how combining ACC inhibition with FGF19 reduced triglyceride accumulation and fibrosis in human precision-cut liver slices.
The evidence your program demands
Speak to our team about your program.